BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23070161)

  • 1. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
    Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
    Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.
    Sakoulas G; Rose W; Nonejuie P; Olson J; Pogliano J; Humphries R; Nizet V
    Antimicrob Agents Chemother; 2014; 58(3):1494-500. PubMed ID: 24366742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
    Werth BJ; Steed ME; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).
    Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT
    Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.
    Barber KE; Werth BJ; Rybak MJ
    J Antimicrob Chemother; 2015 Feb; 70(2):505-9. PubMed ID: 25246437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression.
    Rose WE; Fallon M; Moran JJ; Vanderloo JP
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4422-7. PubMed ID: 22687502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2012 Feb; 56(2):955-9. PubMed ID: 22123693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of ceftaroline against extracellular (broth) and intracellular (THP-1 monocytes) forms of methicillin-resistant Staphylococcus aureus: comparison with vancomycin, linezolid and daptomycin.
    Mélard A; Garcia LG; Das D; Rozenberg R; Tulkens PM; Van Bambeke F; Lemaire S
    J Antimicrob Chemother; 2013 Mar; 68(3):648-58. PubMed ID: 23188792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
    Saravolatz L; Pawlak J; Johnson L
    Antimicrob Agents Chemother; 2010 Jul; 54(7):3027-30. PubMed ID: 20404122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
    Sader HS; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).
    Thitiananpakorn K; Aiba Y; Tan XE; Watanabe S; Kiga K; Sato'o Y; Boonsiri T; Li FY; Sasahara T; Taki Y; Azam AH; Zhang Y; Cui L
    Sci Rep; 2020 Sep; 10(1):16107. PubMed ID: 32999359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.
    Sakoulas G; Rose W; Berti A; Olson J; Munguia J; Nonejuie P; Sakoulas E; Rybak MJ; Pogliano J; Nizet V
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
    Smith JR; Yim J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.
    Sakoulas G; Moise PA; Casapao AM; Nonejuie P; Olson J; Okumura CY; Rybak MJ; Kullar R; Dhand A; Rose WE; Goff DA; Bressler AM; Lee Y; Pogliano J; Johns S; Kaatz GW; Ebright JR; Nizet V
    Clin Ther; 2014 Oct; 36(10):1317-33. PubMed ID: 25017183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
    MacVane SH; So W; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7520-6. PubMed ID: 25288076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.